|
1
|
Bosch FX, Ribes J, Díaz M and Cléries R:
Primary liver cancer: Worldwide incidence and trends.
Gastroenterology. 127(Suppl 1): S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang L, Parkin DM, Whelan S, Zhang S, Chen
Y, Lu F and Li L: Statistics on cancer in China: Cancer
registration in 2002. Eur J Cancer Prev. 14:329–335. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Portolani N, Coniglio A, Ghidoni S,
Giovanelli M, Benetti A, Tiberio GA and Giulini SM: Early and late
recurrence after liver resection for hepatocellular carcinoma:
Prognostic and therapeutic implications. Ann Surg. 243:229–235.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bruix J, Boix L, Sala M and Llovet JM:
Focus on hepatocellular carcinoma. Cancer Cell. 5:215–219. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Poon RT, Fan ST, Lo CM, Liu CL and Wong J:
Intrahepatic recurrence after curative resection of hepatocellular
carcinoma: Long-term results of treatment and prognostic factors.
Ann Surg. 229:216–222. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shimozawa N and Hanazaki K: Longterm
prognosis after hepatic resection for small hepatocellular
carcinoma. J Am Coll Surg. 198:356–365. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bruix J and Sherman M; Practice Guidelines
Committee, American Association for the Study of Liver Diseases:
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Llovet JM, Brú C and Bruix J: Prognosis of
hepatocellular carcinoma: The BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Llovet JM and Bruix J: novel advancements
in the management of hepatocellular carcinoma in 2008. J Hepatol.
48(Suppl 1): S20–S37. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Izumi R, Shimizu K, Ii T, Yagi M, Matsui
O, Nonomura A and Miyazaki I: Prognostic factors of hepatocellular
carcinoma in patients undergoing hepatic resection.
Gastroenterology. 106:720–727. 1994.PubMed/NCBI
|
|
11
|
Iizuka N, Oka M, Yamada-Okabe H, Nishida
M, Maeda Y, Mori N, Takao T, Tamesa T, Tangoku A, Tabuchi H, et al:
Oligonucleotide microarray for prediction of early intrahepatic
recurrence of hepatocellular carcinoma after curative resection.
Lancet. 361:923–929. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hoshida Y, Villanueva A, Kobayashi M, Peix
J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, et
al: Gene expression in fixed tissues and outcome in hepatocellular
carcinoma. N Engl J Med. 359:1995–2004. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Greenwald I: LIN-12/Notch signaling:
Lessons from worms and flies. Genes Dev. 12:1751–1762. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sestan N, Artavanis-Tsakonas S and Rakic
P: Contact-dependent inhibition of cortical neurite growth mediated
by Notch signaling. Science. 286:741–746. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dontu G, Jackson KW, McNicholas E,
Kawamura MJ, Abdallah WM and Wicha MS: Role of Notch signaling in
cell-fate determination of human mammary stem/progenitor cells.
Breast Cancer Res. 6:R605–R615. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ellisen LW, Bird J, West DC, Soreng AL,
Reynolds TC, Smith SD and Sklar J: TAN-1, the human homolog of the
Drosophila Notch gene, is broken by chromosomal translocations in T
lymphoblastic neoplasms. Cell. 66:649–661. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weng AP and Aster JC: Multiple niches for
Notch in cancer: Context is everything. Curr Opin Genet Dev.
14:48–54. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fan X, Matsui W, Khaki L, Stearns D, Chun
J, Li YM and Eberhart CG: Notch pathway inhibition depletes
stem-like cells and blocks engraftment in embryonal brain tumors.
Cancer Res. 66:7445–7452. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dufraine J, Funahashi Y and Kitajewski J:
Notch signaling regulates tumor angiogenesis by diverse mechanisms.
Oncogene. 27:5132–5137. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qi R, An H, Yu Y, Zhang M, Liu S, Xu H,
Guo Z, Cheng T and Cao X: Notch1 signaling inhibits growth of human
hepatocellular carcinoma through induction of cell cycle arrest and
apoptosis. Cancer Res. 63:8323–8329. 2003.PubMed/NCBI
|
|
21
|
Wang C, Qi R, Li N, Wang Z, An H, Zhang Q,
Yu Y and Cao X: Notch1 signaling sensitizes TRAIL-induced apoptosis
in human hepatocellular carcinoma cells by inhibiting
Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent
DR5 expression. J Biol Chem. 284:16183–16190. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu J, Yun X, Jiang J, Wei Y, Wu Y, Zhang
W, Liu Y, Wang W, Wen Y and Gu J: Hepatitis B virus X protein
blunts senescence-like growth arrest of human hepatocellular
carcinoma via reducing Notch1 cleavage. Hepatology. 52:142–154.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang K, Liu J, Yan ZL, Li J, Shi LH, Cong
WM, Xia Y, Zou QF, Xi T, Shen F, et al: Overexpression of
aspartyl-(asparaginyl)-β-hydroxylase in hepatocellular carcinoma is
associated with worse surgical outcome. Hepatology. 52:164–173.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sobin Lh and Wittekind C: TNM
Classification of Malignant Tumors. 6th edition. Wiley-Liss; New
York: pp. 81–83. 2002
|
|
25
|
Llovet JM, Di Bisceglie AM, Bruix J,
Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M,
Talwalkar J, et al Panel of Experts in HCC-Design Clinical Trials:
Design and endpoints of clinical trials in hepatocellular
carcinoma. J Natl Cancer Inst. 100:698–711. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Talwalkar JA and Gores GJ: Diagnosis and
staging of hepatocellular carcinoma. Gastroenterology. 127(Suppl
1): S126–S132. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamamoto J, Kosuge T, Saiura A, Sakamoto
Y, Shimada K, Sano T, Takayama T, Sugawara Y, Yamaguchi T, Kokudo
N, et al: Effectiveness of hepatic resection for early-stage
hepatocellular carcinoma in cirrhotic patients: Subgroup analysis
according to Milan criteria. Jpn J Clin Oncol. 37:287–295. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mazzaferro V, Regalia E, Doci R, Andreola
S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A and
Gennari L: Liver transplantation for the treatment of small
hepatocellular carcinomas in patients with cirrhosis. N Engl J Med.
334:693–699. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vauthey JN, Lauwers GY, Esnaola NF, Do KA,
Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau JM, Rashid A,
et al: Simplified staging for hepatocellular carcinoma. J Clin
Oncol. 20:1527–1536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yin L, Velazquez OC and Liu ZJ: Notch
signaling: Emerging molecular targets for cancer therapy. Biochem
Pharmacol. 80:690–701. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Weng AP, Millholland JM, Yashiro-Ohtani Y,
Arcangeli ML, Lau A, Wai C, Del Bianco C, Rodriguez CG, Sai H,
Tobias J, et al: c-Myc is an important direct target of Notch1 in
T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev.
20:2096–2109. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rangarajan A, Talora C, Okuyama R, Nicolas
M, Mammucari C, Oh H, Aster JC, Krishna S, Metzger D, Chambon P, et
al: Notch signaling is a direct determinant of keratinocyte growth
arrest and entry into differentiation. EMBO J. 20:3427–3436. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nicolas M, Wolfer A, Raj K, Kummer JA,
Mill P, van noort M, Hui CC, Clevers H, Dotto GP and Radtke F:
Notch1 functions as a tumor suppressor in mouse skin. Nat Genet.
33:416–421. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang M, Xue L, Cao Q, Lin Y, Ding Y, Yang
P and Che L: Expression of Notch1, Jagged1 and β-catenin and their
clinicopathological significance in hepatocellular carcinoma.
Neoplasma. 56:533–541. 2009. View Article : Google Scholar
|
|
35
|
Bruix J and Llovet JM: Prognostic
prediction and treatment strategy in hepatocellular carcinoma.
Hepatology. 35:519–524. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR
and Ma ZC: Microvessel density of hepatocellular carcinoma: Its
relationship with prognosis. J Cancer Res Clin Oncol. 125:419–426.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan
ST and Wong J: Tumor microvessel density as a predictor of
recurrence after resection of hepatocellular carcinoma: A
prospective study. J Clin Oncol. 20:1775–1785. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Leong KG, Niessen K, Kulic I, Raouf A,
Eaves C, Pollet I and Karsan A: Jagged1-mediated Notch activation
induces epithelial-to-mesenchymal transition through Slug-induced
repression of E-cadherin. J exp Med. 204:2935–2948. 2007.
View Article : Google Scholar : PubMed/NCBI
|
